Trial Title:
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
NCT ID:
NCT05554354
Condition:
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic HER2-Negative Breast Carcinoma
Metastatic Hormone Receptor-Positive Breast Carcinoma
Conditions: Official terms:
Carcinoma
Breast Neoplasms
Fulvestrant
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Binimetinib
Description:
Given PO
Arm group label:
Cohort I (Arm I) (fulvestrant, binimetinib)
Arm group label:
Cohort II (fulvestrant, binimetinib)
Other name:
ARRY 162
Other name:
ARRY 438162
Other name:
ARRY-162
Other name:
ARRY-438162
Other name:
ARRY162
Other name:
ARRY438162
Other name:
MEK 162
Other name:
MEK-162
Other name:
MEK162
Other name:
Mektovi
Intervention type:
Procedure
Intervention name:
Biopsy
Description:
Undergo tumor biopsy
Arm group label:
Cohort I (Arm I) (fulvestrant, binimetinib)
Arm group label:
Cohort I (Arm II)
Arm group label:
Cohort II (fulvestrant, binimetinib)
Other name:
BIOPSY_TYPE
Other name:
Bx
Intervention type:
Procedure
Intervention name:
Biospecimen Collection
Description:
Undergo blood sample collection
Arm group label:
Cohort I (Arm I) (fulvestrant, binimetinib)
Arm group label:
Cohort I (Arm II)
Arm group label:
Cohort II (fulvestrant, binimetinib)
Other name:
Biological Sample Collection
Other name:
Biospecimen Collected
Other name:
Specimen Collection
Intervention type:
Procedure
Intervention name:
Bone Scan
Description:
Undergo bone scan
Arm group label:
Cohort I (Arm I) (fulvestrant, binimetinib)
Arm group label:
Cohort I (Arm II)
Arm group label:
Cohort II (fulvestrant, binimetinib)
Other name:
Bone Scintigraphy
Intervention type:
Procedure
Intervention name:
Computed Tomography
Description:
Undergo CT scan
Arm group label:
Cohort I (Arm I) (fulvestrant, binimetinib)
Arm group label:
Cohort I (Arm II)
Arm group label:
Cohort II (fulvestrant, binimetinib)
Other name:
CAT
Other name:
CAT Scan
Other name:
Computed Axial Tomography
Other name:
Computerized Axial Tomography
Other name:
Computerized axial tomography (procedure)
Other name:
Computerized Tomography
Other name:
Computerized Tomography (CT) scan
Other name:
CT
Other name:
CT Scan
Other name:
tomography
Intervention type:
Procedure
Intervention name:
Echocardiography
Description:
Undergo ECHO
Arm group label:
Cohort I (Arm I) (fulvestrant, binimetinib)
Arm group label:
Cohort I (Arm II)
Arm group label:
Cohort II (fulvestrant, binimetinib)
Other name:
EC
Intervention type:
Drug
Intervention name:
Fulvestrant
Description:
Given IM
Arm group label:
Cohort I (Arm I) (fulvestrant, binimetinib)
Arm group label:
Cohort I (Arm II)
Arm group label:
Cohort II (fulvestrant, binimetinib)
Other name:
Faslodex
Other name:
Faslodex(ICI 182,780)
Other name:
ICI 182,780
Other name:
ICI 182780
Other name:
ICI-182780
Other name:
ICI182780
Other name:
ZD 9238
Other name:
ZD-9238
Other name:
ZD9238
Intervention type:
Procedure
Intervention name:
Magnetic Resonance Imaging
Description:
Undergo MRI
Arm group label:
Cohort I (Arm I) (fulvestrant, binimetinib)
Arm group label:
Cohort I (Arm II)
Arm group label:
Cohort II (fulvestrant, binimetinib)
Other name:
Magnetic Resonance
Other name:
Magnetic Resonance Imaging (MRI)
Other name:
Magnetic resonance imaging (procedure)
Other name:
Magnetic Resonance Imaging Scan
Other name:
Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
Other name:
MR
Other name:
MR Imaging
Other name:
MRI
Other name:
MRI Scan
Other name:
MRIs
Other name:
NMR Imaging
Other name:
NMRI
Other name:
Nuclear Magnetic Resonance Imaging
Other name:
sMRI
Other name:
Structural MRI
Intervention type:
Procedure
Intervention name:
Multigated Acquisition Scan
Description:
Undergo MUGA
Arm group label:
Cohort I (Arm I) (fulvestrant, binimetinib)
Arm group label:
Cohort I (Arm II)
Arm group label:
Cohort II (fulvestrant, binimetinib)
Other name:
Blood Pool Scan
Other name:
Equilibrium Radionuclide Angiography
Other name:
Gated Blood Pool Imaging
Other name:
Gated Heart Pool Scan
Other name:
MUGA
Other name:
MUGA Scan
Other name:
Multi-Gated Acquisition Scan
Other name:
Radionuclide Ventriculogram Scan
Other name:
Radionuclide Ventriculography
Other name:
RNV Scan
Other name:
RNVG
Other name:
SYMA Scanning
Other name:
Synchronized Multigated Acquisition Scanning
Summary:
This phase II ComboMATCH treatment trial compares the usual treatment alone (fulvestrant)
to using binimetinib plus the usual treatment in patients with hormone receptor positive
breast cancer that has spread from where it first started to other places in the body
(metastatic) and has an NF1 genetic change. Fulvestrant is a hormonal therapy that binds
to estrogen receptors in tumor cells, resulting in estrogen receptor destruction and
decreased estrogen binding, which may inhibit the growth of estrogen-sensitive tumor
cells. Binimetinib is a targeted therapy that may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. The addition of binimetinib to
fulvestrant in breast cancers with an NF1 genetic change could increase the percentage of
tumors that shrink as well as lengthen the time that the tumors remain stable (without
progression) as compared to fulvestrant alone.
Detailed description:
PRIMARY OBJECTIVES:
I. To determine whether the combination of fulvestrant and binimetinib improves
progression-free survival (PFS) compared to treatment with fulvestrant alone in patients
not previously treated with fulvestrant. (Cohort 1) II. To determine whether overall
response rate (ORR) within 4 months in patients who have previously progressed on a
fulvestrant-containing regimen is greater than 10%, as a historical comparison, when
these patients receive combination fulvestrant and binimetinib therapy. (Cohort 2)
SECONDARY OBJECTIVES:
I. To estimate ORR at any time after the start of the treatment for Cohort 2 and
separately for the two arms in Cohort 1.
II. To estimate PFS distribution in Cohort 2. III. To estimate clinical benefit rate
separately for the two arms in Cohort 1 and Cohort 2.
IV. To determine the safety and toxicity profile in both cohorts. V. To estimate the
overall survival (OS) in both cohorts. VI. Collect tissue and provide it to the
ComboMATCH Registration Protocol to assess concordance between the diagnostic tumor
mutation profile generated by the Designated Laboratories, the pre-treatment biopsy
mutation profile, and the pre-treatment circulating tumor deoxyribonucleic acid (DNA)
(ctDNA) mutation profile from plasma, as described in ComboMATCH Registration Protocol.
For this treatment substudy, the outcome objective will be to report the proportion of
cases providing sufficient tissue for that integrated scientific activity in the
ComboMATCH Registration Protocol.
EXPLORATORY BIOMARKER OBJECTIVES:
I. To analyze the cell-free (cf)DNA at progression to determine the changes in cfDNA
profile in order to understand blood-based mutation dynamics.
II. To analyze RNAseq at progression to determine potential pathways that are altered
that may contribute to the sensitivity/resistance.
III. To discover/detect novel biomarkers using microscaled proteogenomics by analyzing
the proteins and phosphor-proteins along with genomics to determine potential pathways
that may correlate with the response to the combination treatment.
IV. To detect the loss of NF1, using immunohistochemistry staining to precisely measure
the level of the NF1 protein.
V. To determine the variant allele frequency (VAF) of mutant NF1 measuring by using
droplet digital polymerase chain reaction (ddPCR) for the targeted NF1 gene level.
OUTLINE: Patients who are fulvestrant naive are assigned to Cohort I, while patients who
are fulvestrant resistant are assigned to Cohort II.
COHORT I: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive fulvestrant intramuscularly (IM) on day 1 and day 15 of cycle 1
and day 1 of subsequent cycles and binimetinib orally (PO) twice daily (BID) on days 15
to 28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days
in the absence of disease progression or unacceptable toxicity. Patients also undergo a
computed tomography (CT), magnetic resonance imaging (MRI), or bone scan,
echocardiography (ECHO) or multi-gated acqusition scan (MUGA), and tumor biopsy, as well
as possible blood sample collection during screening and on study.
ARM II: Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of
subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or
unacceptable toxicity. Patients who progress on fulvestrant alone may migrate to cohort
II if they meet the migration eligibility criteria. Patients not willing to migrate to
cohort II will have further therapy at the investigator's discretion. Patients undergo a
CT, MRI, or bone scan and tumor biopsy, as well as ECHO or MUGA and possible blood sample
collection during screening and on study.
COHORT II: Patients receive fulvestrant IM on day 1 of each cycle and binimetinib PO BID
on days 15-28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every
28 days in the absence of disease progression or unacceptable toxicity. Patients undergo
a CT, MRI, or bone scan, ECHO or MUGA and tumor biopsy, as well as possible blood sample
collection during screening and on study.
Upon completion of study treatment patients are followed up every 6 months for 5 years.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patient must have enrolled onto EAY191 and must have been given a treatment
assignment to ComboMATCH to EAY191-N2 based on the presence of an actionable
mutation as defined in EAY191
- The patient must be enrolled on the ComboMATCH Master Registration Trial EAY191
- Note: Patients must fulfill all eligibility criteria outlined in the ComboMATCH
Registration Trial EAY191 at the time of registration to EAY191-N2. This
includes submission of next-generation sequencing (NGS) data from one of the
National Cancer Institute (NCI) credentialed designated laboratories for all
potential patients prior to treatment trial assignment. Copy number and allele
frequency cutoff as per the Registration protocol
- Patients must have disease that can be safely biopsied and agree to a pre-treatment
biopsy or, if disease cannot be safely biopsied, have archival tissue available from
within 12 months prior to the date of registration on the ComboMATCH registration
trial (EAY191)
- Please note the current actionable marker of interest (aMOI)/actionable
alteration list for this treatment trial can be found on the Cancer Trial
Support Unit (CTSU) ComboMATCH Registration protocol page
- Please note novel/Dynamic aMOI can be submitted for review per the process
described in the ComboMATCH Registration protocol
- A COMBOMATCH TREATMENT TRIAL EAY191-N2 ELIGIBILITY CRITERIA:
- The patient or a legally authorized representative must provide study-specific
informed consent prior to study entry and, for patients treated in the United States
(U.S.), authorization permitting release of personal health information
- Age >= 18
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Histologically or cytologically confirmed invasive breast carcinoma
- Confirmed metastatic disease by either imaging or tissue diagnosis
- Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and
one additional lesion that can be biopsied (primary, metastatic both allowed)
- Patients must have inactivating or inferred inactivating NF1 alterations detected in
tumor as determined by the ComboMATCH screening assessment
- The tumor must have been determined to be estrogen receptor (ER) and/or progesterone
receptor (PgR) positive assessed by current American Society of Clinical Oncology
(ASCO)/College of American Pathologists (CAP) guideline recommendations for hormone
receptor testing. Patients with >= 1% ER or PgR staining by immunohistochemistry
(IHC) are considered positive
- The tumor must have been determined to be HER2-negative by current ASCO/CAP
guidelines
- Prior use of CDK4/6 inhibitor(i) is required
- Prior use of fulvestrant regardless of duration is allowed and will determine
treatment assignment
- Up to one line of chemotherapy in metastatic setting is allowed
- Absolute neutrophil count >= 1,500/mm^3
- Platelet count >= 100,000/ mm^3
- Hemoglobin level >= 10 g/dL
- Creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula
- Total bilirubin level =< institutional upper limit of normal
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 5.0 x
ULN
- For patients who will be assigned to Cohort 2 (fulvestrant-resistant), a left
ventricular ejection fraction (LVEF) assessment must be performed within 12 weeks
prior to registration. The LVEF must be >= 50% regardless of the cardiac imaging
facility's lower limit of normal. (LVEF assessment performed by echocardiogram is
preferred; however, MUGA scan may be substituted based on institutional/situational
preferences)
- Patients with a prior or concurrent malignancy whose natural history or treatment
does not have the potential to interfere with the safety or efficacy assessment of
the investigational regimen are eligible for this trial
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral
therapy with undetectable viral load within 6 months of registration are eligible
for this trial
- ELIGIBILITY CRITERIA FOR COHORT 1, TREATMENT REGIMEN 2 PATIENTS WHO MIGRATE TO
COHORT 2: Cohort migration: Patients treated with control treatment fulvestrant who
experience disease progression may be eligible to migrate to Cohort 2 and receive
combination treatment with binimetinib and fulvestrant. Patients who choose to do so
must meet laboratory values and performance status requirements below and should
begin treatment within 28 days
- PATIENTS WHO MIGRATE TO COHORT 2: Patient's willingness to migrate to Cohort 2
affirmed
- PATIENTS WHO MIGRATE TO COHORT 2: The patient must have an ECOG performance status
of 0-2
- PATIENTS WHO MIGRATE TO COHORT 2: Absolute neutrophil count >= 1,500/mm^3
- PATIENTS WHO MIGRATE TO COHORT 2: Platelet count >= 100,000/ mm^3
- PATIENTS WHO MIGRATE TO COHORT 2: Hemoglobin level >= 10 g/dL
- PATIENTS WHO MIGRATE TO COHORT 2: Total bilirubin level =< institutional upper limit
of normal (ULN)
- PATIENTS WHO MIGRATE TO COHORT 2: AST and ALT must be =< 5.0 x ULN
- PATIENTS WHO MIGRATE TO COHORT 2: Creatinine clearance (CrCL) of ≥30 mL/min by the
Cockcroft-Gault formula
- PATIENTS WHO MIGRATE TO COHORT 2: A LVEF performed within the last 3 months must be
>= 50% regardless of the cardiac imaging facility's lower limit of normal (LVEF
assessment performed by echocardiogram is preferred; however, MUGA scan may be
substituted based on institutional/situational preferences)
- PATIENTS WHO MIGRATE TO COHORT 2: Pregnancy test according to institutional
standards must be negative (for patients of childbearing potential only)
Exclusion Criteria:
- Concurrent anticancer therapy
- Active autoimmune disease requiring systemic treatment within the past 3 months,
documented history of clinically severe autoimmune disease, or a syndrome that
requires systemic steroids or immunosuppressive agents
- Active brain metastasis. Brain metastases that have been stable for at least 1 month
after completion of treatment are not an exclusion criterion
- History of or evidence of retinal pathology on ophthalmologic examination that is
considered a risk factor for neurosensory retinal detachment/central serous,
chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular
degeneration
- Patients will be excluded if they currently have the following risk factors for RVO
that are documented prior to the enrollment:
- Known uncontrolled glaucoma with intra-ocular pressures >= 21 mmHg
- Known serum cholesterol >= grade 2.
- Known hypertriglyceridemia >= grade 2
- Known hyperglycemia (fasting) >= grade 2
- Patients with baseline QT corrected for heart rate (QTc) > 500 ms, either induced by
medication or congenital long QT syndrome will be excluded due to known side effects
of binimetinib
- Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral
sensory neuropathy) >= grade 2
- Patients with known history or current symptoms of cardiac disease, or history of
treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac
function using the New York Heart Association Functional Classification. To be
eligible for this trial, patients should be class 2B or better
- Any other disease, metabolic dysfunction, physical examination finding, or clinical
laboratory finding giving reasonable suspicion of a disease or condition that
contraindicates the use of an investigational drug or that may affect the
interpretation of the results or render the patient at high risk from treatment
complications
- Other conditions that, in the opinion of the investigator, would preclude the
patient from meeting the study requirements or interfere with interpretation of
study results
- Pregnancy or lactation at the time of registration or intention to become pregnant
during the study (Note: Pregnancy testing according to institutional standards for
patients of childbearing potential)
- For binimetinib, highly effective contraception should be used for at least 30
days after the last dose, and patients should not breastfeed for 3 days after
the last dose
- For fulvestrant, highly effective contraception should be used for 1 year after
the last dose, and patients should not breastfeed for 1 year after the last
dose
- Use of any investigational product within 30 days prior to study entry
- INELIGIBILITY CRITERIA FOR COHORT 1, TREATMENT REGIMEN 2 PATIENTS WHO MIGRATE TO
COHORT 2
- PATIENTS WHO MIGRATE TO COHORT 2: Not a candidate for binimetinib in the opinion of
the treating investigator
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University of Alabama at Birmingham Cancer Center
Address:
City:
Birmingham
Zip:
35233
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
205-934-0220
Email:
tmyrick@uab.edu
Investigator:
Last name:
Rebecca C. Arend
Email:
Principal Investigator
Facility:
Name:
Kingman Regional Medical Center
Address:
City:
Kingman
Zip:
86401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
PCR Oncology
Address:
City:
Arroyo Grande
Zip:
93420
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
Epic Care-Dublin
Address:
City:
Dublin
Zip:
94568
Country:
United States
Status:
Active, not recruiting
Facility:
Name:
Epic Care Partners in Cancer Care
Address:
City:
Emeryville
Zip:
94608
Country:
United States
Status:
Active, not recruiting
Facility:
Name:
Contra Costa Regional Medical Center
Address:
City:
Martinez
Zip:
94553-3156
Country:
United States
Status:
Suspended
Facility:
Name:
Saint Joseph Hospital - Orange
Address:
City:
Orange
Zip:
92868
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
714-734-6220
Investigator:
Last name:
Timothy E. Byun
Email:
Principal Investigator
Facility:
Name:
Saint John's Cancer Institute
Address:
City:
Santa Monica
Zip:
90404
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
310-582-7448
Investigator:
Last name:
Reva K. Basho
Email:
Principal Investigator
Facility:
Name:
Epic Care Cyberknife Center
Address:
City:
Walnut Creek
Zip:
94597
Country:
United States
Status:
Active, not recruiting
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Aventura
Address:
City:
Aventura
Zip:
33180
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
954-461-2180
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Coral Gables
Address:
City:
Coral Gables
Zip:
33146
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Address:
City:
Deerfield Beach
Zip:
33442
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
Mayo Clinic in Florida
Address:
City:
Jacksonville
Zip:
32224-9980
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
855-776-0015
Investigator:
Last name:
Karthik V. Giridhar
Email:
Principal Investigator
Facility:
Name:
University of Miami Miller School of Medicine-Sylvester Cancer Center
Address:
City:
Miami
Zip:
33136
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Kendall
Address:
City:
Miami
Zip:
33176
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Plantation
Address:
City:
Plantation
Zip:
33324
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Boise
Address:
City:
Boise
Zip:
83706
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-3671
Email:
stephanie.couch@stjoeshealth.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Boise
Address:
City:
Boise
Zip:
83712
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Caldwell
Address:
City:
Caldwell
Zip:
83605
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-3671
Email:
stephanie.couch@stjoeshealth.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Health - Coeur d'Alene
Address:
City:
Coeur d'Alene
Zip:
83814
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Fruitland
Address:
City:
Fruitland
Zip:
83619
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Meridian
Address:
City:
Meridian
Zip:
83642
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Nampa
Address:
City:
Nampa
Zip:
83687
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Nampa
Address:
City:
Nampa
Zip:
83687
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Post Falls
Address:
City:
Post Falls
Zip:
83854
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Sandpoint
Address:
City:
Sandpoint
Zip:
83864
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Twin Falls
Address:
City:
Twin Falls
Zip:
83301
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Advocate Good Shepherd Hospital
Address:
City:
Barrington
Zip:
60010
Country:
United States
Status:
Suspended
Facility:
Name:
Northwestern University
Address:
City:
Chicago
Zip:
60611
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-695-1301
Email:
cancer@northwestern.edu
Investigator:
Last name:
Lisa E. Flaum
Email:
Principal Investigator
Facility:
Name:
John H Stroger Jr Hospital of Cook County
Address:
City:
Chicago
Zip:
60612
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-864-5204
Investigator:
Last name:
Thomas E. Lad
Email:
Principal Investigator
Facility:
Name:
Advocate Illinois Masonic Medical Center
Address:
City:
Chicago
Zip:
60657
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
773-296-5360
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
AMG Crystal Lake - Oncology
Address:
City:
Crystal Lake
Zip:
60014
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-929-6129
Email:
advocateresearch@advocate.com
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Carle at The Riverfront
Address:
City:
Danville
Zip:
61832
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@Carle.com
Investigator:
Last name:
Pratima Chalasani
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Cancer Center Kishwaukee
Address:
City:
DeKalb
Zip:
60115
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-352-5360
Email:
Donald.Smith3@nm.org
Investigator:
Last name:
Lisa E. Flaum
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Effingham
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Pratima Chalasani
Email:
Principal Investigator
Facility:
Name:
Advocate Sherman Hospital
Address:
City:
Elgin
Zip:
60123
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
847-429-2907
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Cancer Center Delnor
Address:
City:
Geneva
Zip:
60134
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-352-5360
Email:
Donald.Smith3@nm.org
Investigator:
Last name:
Lisa E. Flaum
Email:
Principal Investigator
Facility:
Name:
Advocate South Suburban Hospital
Address:
City:
Hazel Crest
Zip:
60429
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
708-799-9995
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Lake Forest Hospital
Address:
City:
Lake Forest
Zip:
60045
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
cancertrials@northwestern.edu
Investigator:
Last name:
Lisa E. Flaum
Email:
Principal Investigator
Facility:
Name:
AMG Libertyville - Oncology
Address:
City:
Libertyville
Zip:
60048
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-929-6129
Email:
advocateresearch@advocatehealth.com
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Condell Memorial Hospital
Address:
City:
Libertyville
Zip:
60048
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-929-6129
Email:
advocateresearch@advocatehealth.com
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Mattoon/Charleston
Address:
City:
Mattoon
Zip:
61938
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Pratima Chalasani
Email:
Principal Investigator
Facility:
Name:
Advocate Christ Medical Center
Address:
City:
Oak Lawn
Zip:
60453-2699
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-323-8622
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Orland Park
Address:
City:
Orland Park
Zip:
60462
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
nctnprogram_rhlccc@northwestern.edu
Investigator:
Last name:
Lisa E. Flaum
Email:
Principal Investigator
Facility:
Name:
Advocate Lutheran General Hospital
Address:
City:
Park Ridge
Zip:
60068
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
847-384-3621
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Memorial Hospital East
Address:
City:
Shiloh
Zip:
62269
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-747-9912
Email:
dschwab@wustl.edu
Investigator:
Last name:
Andrew Davis
Email:
Principal Investigator
Facility:
Name:
Carle Cancer Center
Address:
City:
Urbana
Zip:
61801
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Pratima Chalasani
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Cancer Center Warrenville
Address:
City:
Warrenville
Zip:
60555
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-352-5360
Email:
Donald.Smith3@nm.org
Investigator:
Last name:
Lisa E. Flaum
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Ankeny
Address:
City:
Ankeny
Zip:
50023
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-282-2921
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Des Moines
Address:
City:
Des Moines
Zip:
50309
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-241-3305
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
Mercy Medical Center - Des Moines
Address:
City:
Des Moines
Zip:
50314
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-358-6613
Email:
cancerresearch@mercydesmoines.org
Investigator:
Last name:
Richard L. Deming
Email:
Principal Investigator
Facility:
Name:
University of Kentucky/Markey Cancer Center
Address:
City:
Lexington
Zip:
40536
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
859-257-3379
Investigator:
Last name:
Susanne M. Arnold
Email:
Principal Investigator
Facility:
Name:
Lafayette Family Cancer Center-EMMC
Address:
City:
Brewer
Zip:
04412
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-987-3005
Investigator:
Last name:
Sarah J. Sinclair
Email:
Principal Investigator
Facility:
Name:
University of Maryland/Greenebaum Cancer Center
Address:
City:
Baltimore
Zip:
21201
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-888-8823
Investigator:
Last name:
Ranee Mehra
Email:
Principal Investigator
Facility:
Name:
National Institutes of Health Clinical Center
Address:
City:
Bethesda
Zip:
20892
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-411-1222
Investigator:
Last name:
Jibran Ahmed
Email:
Principal Investigator
Facility:
Name:
UPMC Western Maryland
Address:
City:
Cumberland
Zip:
21502
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
240-964-1400
Investigator:
Last name:
Julia Foldi
Email:
Principal Investigator
Facility:
Name:
Tufts Medical Center
Address:
City:
Boston
Zip:
02111
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
617-636-5000
Email:
ContactUsCancerCenter@TuftsMedicalCenter.org
Investigator:
Last name:
Rachel J. Buchsbaum
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Address:
City:
Ann Arbor
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health Dearborn Hospital
Address:
City:
Dearborn
Zip:
48124
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Corewell Health Farmington Hills Hospital
Address:
City:
Farmington Hills
Zip:
48336
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Genesee Cancer and Blood Disease Treatment Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesee Hematology Oncology PC
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesys Hurley Cancer Institute
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Hurley Medical Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
University of Michigan Health - Sparrow Lansing
Address:
City:
Lansing
Zip:
48912
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
517-364-3712
Email:
harsha.trivedi@umhsparrow.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Mary Mercy Livonia Hospital
Address:
City:
Livonia
Zip:
48154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Henry Ford Saint John Hospital - Macomb Medical
Address:
City:
Macomb
Zip:
48044
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health William Beaumont University Hospital
Address:
City:
Royal Oak
Zip:
48073
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
MyMichigan Medical Center Saginaw
Address:
City:
Saginaw
Zip:
48601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Oncology Hematology Associates of Saginaw Valley PC
Address:
City:
Saginaw
Zip:
48604
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
989-907-8411
Email:
lori.srebinski@ascension.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
MyMichigan Medical Center Tawas
Address:
City:
Tawas City
Zip:
48764
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health Beaumont Troy Hospital
Address:
City:
Troy
Zip:
48085
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Saint Mary's Oncology/Hematology Associates of West Branch
Address:
City:
West Branch
Zip:
48661
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
989-907-8411
Email:
lori.srebinski@ascension.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Huron Gastroenterology PC
Address:
City:
Ypsilanti
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Address:
City:
Ypsilanti
Zip:
48197
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Sanford Joe Lueken Cancer Center
Address:
City:
Bemidji
Zip:
56601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-333-5000
Email:
OncologyClinicalTrialsFargo@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Mercy Hospital
Address:
City:
Coon Rapids
Zip:
55433
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Yan Ji
Email:
Principal Investigator
Facility:
Name:
Essentia Health - Deer River Clinic
Address:
City:
Deer River
Zip:
56636
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Cancer Center
Address:
City:
Duluth
Zip:
55805
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Fairview Southdale Hospital
Address:
City:
Edina
Zip:
55435
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Yan Ji
Email:
Principal Investigator
Facility:
Name:
Essentia Health Hibbing Clinic
Address:
City:
Hibbing
Zip:
55746
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Saint John's Hospital - Healtheast
Address:
City:
Maplewood
Zip:
55109
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Yan Ji
Email:
Principal Investigator
Facility:
Name:
Abbott-Northwestern Hospital
Address:
City:
Minneapolis
Zip:
55407
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Yan Ji
Email:
Principal Investigator
Facility:
Name:
Mayo Clinic in Rochester
Address:
City:
Rochester
Zip:
55905
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
855-776-0015
Investigator:
Last name:
Karthik V. Giridhar
Email:
Principal Investigator
Facility:
Name:
Park Nicollet Clinic - Saint Louis Park
Address:
City:
Saint Louis Park
Zip:
55416
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Yan Ji
Email:
Principal Investigator
Facility:
Name:
Regions Hospital
Address:
City:
Saint Paul
Zip:
55101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Yan Ji
Email:
Principal Investigator
Facility:
Name:
United Hospital
Address:
City:
Saint Paul
Zip:
55102
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Yan Ji
Email:
Principal Investigator
Facility:
Name:
Essentia Health Sandstone
Address:
City:
Sandstone
Zip:
55072
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Virginia Clinic
Address:
City:
Virginia
Zip:
55792
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Gulfport Memorial Hospital
Address:
City:
Gulfport
Zip:
39502
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
504-210-3539
Email:
emede1@lsuhsc.edu
Investigator:
Last name:
Augusto C. Ochoa
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at West County Hospital
Address:
City:
Creve Coeur
Zip:
63141
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Andrew Davis
Email:
Principal Investigator
Facility:
Name:
Washington University School of Medicine
Address:
City:
Saint Louis
Zip:
63110
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Andrew Davis
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center-South County
Address:
City:
Saint Louis
Zip:
63129
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Andrew Davis
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Christian Hospital
Address:
City:
Saint Louis
Zip:
63136
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Andrew Davis
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Saint Peters Hospital
Address:
City:
Saint Peters
Zip:
63376
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Andrew Davis
Email:
Principal Investigator
Facility:
Name:
Community Hospital of Anaconda
Address:
City:
Anaconda
Zip:
59711
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Billings Clinic Cancer Center
Address:
City:
Billings
Zip:
59101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-996-2663
Email:
research@billingsclinic.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Bozeman Health Deaconess Hospital
Address:
City:
Bozeman
Zip:
59715
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Benefis Sletten Cancer Institute
Address:
City:
Great Falls
Zip:
59405
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Logan Health Medical Center
Address:
City:
Kalispell
Zip:
59901
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Community Medical Center
Address:
City:
Missoula
Zip:
59804
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Seven Hills
Address:
City:
Henderson
Zip:
89052
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Charleston
Address:
City:
Las Vegas
Zip:
89102
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Fort Apache
Address:
City:
Las Vegas
Zip:
89148
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
Montefiore Medical Center-Einstein Campus
Address:
City:
Bronx
Zip:
10461
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
718-379-6866
Email:
eskwak@montefiore.org
Investigator:
Last name:
Jesus D. Anampa Mesias
Email:
Principal Investigator
Facility:
Name:
Sanford Bismarck Medical Center
Address:
City:
Bismarck
Zip:
58501
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
701-323-5760
Email:
OncologyClinicalTrialsFargo@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Sanford Broadway Medical Center
Address:
City:
Fargo
Zip:
58122
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
701-323-5760
Email:
OncologyClinicalTrialsFargo@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Sanford Roger Maris Cancer Center
Address:
City:
Fargo
Zip:
58122
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
701-234-6161
Email:
OncologyClinicalTrialsFargo@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Strecker Cancer Center-Belpre
Address:
City:
Belpre
Zip:
45714
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Aultman Health Foundation
Address:
City:
Canton
Zip:
44710
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
330-363-7274
Email:
ClinicalReserachDept@aultman.com
Investigator:
Last name:
Sunitha Vemulapalli
Email:
Principal Investigator
Facility:
Name:
Miami Valley Hospital South
Address:
City:
Centerville
Zip:
45459
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Jhansi L. Koduri
Email:
Principal Investigator
Facility:
Name:
Adena Regional Medical Center
Address:
City:
Chillicothe
Zip:
45601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-779-7585
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Mount Carmel East Hospital
Address:
City:
Columbus
Zip:
43213
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
The Mark H Zangmeister Center
Address:
City:
Columbus
Zip:
43219
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Miami Valley Hospital
Address:
City:
Dayton
Zip:
45409
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Jhansi L. Koduri
Email:
Principal Investigator
Facility:
Name:
Premier Blood and Cancer Center
Address:
City:
Dayton
Zip:
45409
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-276-8320
Investigator:
Last name:
Jhansi L. Koduri
Email:
Principal Investigator
Facility:
Name:
Dayton Physician LLC - Englewood
Address:
City:
Dayton
Zip:
45415
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Miami Valley Hospital North
Address:
City:
Dayton
Zip:
45415
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Jhansi L. Koduri
Email:
Principal Investigator
Facility:
Name:
Atrium Medical Center-Middletown Regional Hospital
Address:
City:
Franklin
Zip:
45005-1066
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Jhansi L. Koduri
Email:
Principal Investigator
Facility:
Name:
Miami Valley Cancer Care and Infusion
Address:
City:
Greenville
Zip:
45331
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-569-7515
Investigator:
Last name:
Jhansi L. Koduri
Email:
Principal Investigator
Facility:
Name:
Kettering Medical Center
Address:
City:
Kettering
Zip:
45429
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Fairfield Medical Center
Address:
City:
Lancaster
Zip:
43130
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Marietta Memorial Hospital
Address:
City:
Marietta
Zip:
45750
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Memorial Hospital
Address:
City:
Marysville
Zip:
43040
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Knox Community Hospital
Address:
City:
Mount Vernon
Zip:
43050
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Licking Memorial Hospital
Address:
City:
Newark
Zip:
43055
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Mercy Health Perrysburg Cancer Center
Address:
City:
Perrysburg
Zip:
43551
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Southern Ohio Medical Center
Address:
City:
Portsmouth
Zip:
45662
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Springfield Regional Cancer Center
Address:
City:
Springfield
Zip:
45504
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Springfield Regional Medical Center
Address:
City:
Springfield
Zip:
45504
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Mercy Health - Saint Anne Hospital
Address:
City:
Toledo
Zip:
43623
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Upper Valley Medical Center
Address:
City:
Troy
Zip:
45373
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Jhansi L. Koduri
Email:
Principal Investigator
Facility:
Name:
Saint Ann's Hospital
Address:
City:
Westerville
Zip:
43081
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Genesis Healthcare System Cancer Care Center
Address:
City:
Zanesville
Zip:
43701
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
University of Oklahoma Health Sciences Center
Address:
City:
Oklahoma City
Zip:
73104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
405-271-8777
Email:
ou-clinical-trials@ouhsc.edu
Investigator:
Last name:
Wajeeha Razaq
Email:
Principal Investigator
Facility:
Name:
Providence Newberg Medical Center
Address:
City:
Newberg
Zip:
97132
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Ontario
Address:
City:
Ontario
Zip:
97914
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Providence Willamette Falls Medical Center
Address:
City:
Oregon City
Zip:
97045
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Providence Portland Medical Center
Address:
City:
Portland
Zip:
97213
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Providence Saint Vincent Medical Center
Address:
City:
Portland
Zip:
97225
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
UPMC Altoona
Address:
City:
Altoona
Zip:
16601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-339-5294
Email:
Roster@nrgoncology.org
Investigator:
Last name:
Julia Foldi
Email:
Principal Investigator
Facility:
Name:
Bryn Mawr Hospital
Address:
City:
Bryn Mawr
Zip:
19010
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
484-476-2649
Email:
turzoe@mlhs.org
Investigator:
Last name:
Paul B. Gilman
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center Erie
Address:
City:
Erie
Zip:
16505
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Julia Foldi
Email:
Principal Investigator
Facility:
Name:
UPMC Cancer Centers - Arnold Palmer Pavilion
Address:
City:
Greensburg
Zip:
15601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
724-838-1900
Investigator:
Last name:
Julia Foldi
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Address:
City:
Mechanicsburg
Zip:
17050
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Julia Foldi
Email:
Principal Investigator
Facility:
Name:
Riddle Memorial Hospital
Address:
City:
Media
Zip:
19063
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
484-476-2649
Email:
turzoe@mlhs.org
Investigator:
Last name:
Paul B. Gilman
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center - Monroeville
Address:
City:
Monroeville
Zip:
15146
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Julia Foldi
Email:
Principal Investigator
Facility:
Name:
Paoli Memorial Hospital
Address:
City:
Paoli
Zip:
19301
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
484-476-2649
Email:
turzoe@mlhs.org
Investigator:
Last name:
Paul B. Gilman
Email:
Principal Investigator
Facility:
Name:
Thomas Jefferson University Hospital
Address:
City:
Philadelphia
Zip:
19107
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
215-600-9151
Email:
ONCTrialNow@jefferson.edu
Investigator:
Last name:
Maysa M. Abu-Khalaf
Email:
Principal Investigator
Facility:
Name:
University of Pittsburgh Cancer Institute (UPCI)
Address:
City:
Pittsburgh
Zip:
15232
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-647-8073
Investigator:
Last name:
Julia Foldi
Email:
Principal Investigator
Facility:
Name:
UPMC-Passavant Hospital
Address:
City:
Pittsburgh
Zip:
15237
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-367-6454
Investigator:
Last name:
Julia Foldi
Email:
Principal Investigator
Facility:
Name:
Asplundh Cancer Pavilion
Address:
City:
Willow Grove
Zip:
19090
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
215-600-9151
Email:
ONCTrialNow@jefferson.edu
Investigator:
Last name:
Maysa M. Abu-Khalaf
Email:
Principal Investigator
Facility:
Name:
Lankenau Medical Center
Address:
City:
Wynnewood
Zip:
19096
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
484-476-2649
Email:
turzoe@mlhs.org
Investigator:
Last name:
Paul B. Gilman
Email:
Principal Investigator
Facility:
Name:
Sanford Cancer Center Oncology Clinic
Address:
City:
Sioux Falls
Zip:
57104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
605-312-3320
Email:
OncologyClinicTrialsSF@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Sanford USD Medical Center - Sioux Falls
Address:
City:
Sioux Falls
Zip:
57117-5134
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
605-312-3320
Email:
OncologyClinicalTrialsSF@SanfordHealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
M D Anderson Cancer Center
Address:
City:
Houston
Zip:
77030
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-632-6789
Email:
askmdanderson@mdanderson.org
Investigator:
Last name:
Funda Meric-Bernstam
Email:
Principal Investigator
Facility:
Name:
Virginia Cancer Institute
Address:
City:
Richmond
Zip:
23229
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
804-287-3000
Email:
smoore@vacancer.com
Investigator:
Last name:
Masey M. Ross
Email:
Principal Investigator
Facility:
Name:
VCU Massey Cancer Center at Stony Point
Address:
City:
Richmond
Zip:
23235
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
ctoclinops@vcu.edu
Investigator:
Last name:
Masey M. Ross
Email:
Principal Investigator
Facility:
Name:
Virginia Commonwealth University/Massey Cancer Center
Address:
City:
Richmond
Zip:
23298
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
CTOclinops@vcu.edu
Investigator:
Last name:
Masey M. Ross
Email:
Principal Investigator
Facility:
Name:
VCU Community Memorial Health Center
Address:
City:
South Hill
Zip:
23970
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
nemer.elmouallem@vcuhealth.org
Investigator:
Last name:
Masey M. Ross
Email:
Principal Investigator
Facility:
Name:
Swedish Cancer Institute-Edmonds
Address:
City:
Edmonds
Zip:
98026
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
206-215-3086
Email:
PCRC-NCORP@Swedish.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Swedish Cancer Institute-Issaquah
Address:
City:
Issaquah
Zip:
98029
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
206-215-3086
Email:
PCRC-NCORP@Swedish.org
Investigator:
Last name:
Dan S. Zuckerman
Email:
Principal Investigator
Facility:
Name:
Valley Medical Center
Address:
City:
Renton
Zip:
98055
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
425-228-3440
Email:
research@valleymed.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Address:
City:
Yakima
Zip:
98902
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
509-574-3535
Email:
Memorial-ClinicalTrials@yvmh.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
Duluth Clinic Ashland
Address:
City:
Ashland
Zip:
54806
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Southern Lakes VLCC
Address:
City:
Burlington
Zip:
53105
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Saint Luke's South Shore
Address:
City:
Cudahy
Zip:
53110
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Health Care Germantown Health Center
Address:
City:
Germantown
Zip:
53022
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Grafton
Address:
City:
Grafton
Zip:
53024
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora BayCare Medical Center
Address:
City:
Green Bay
Zip:
54311
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Kenosha South
Address:
City:
Kenosha
Zip:
53142
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Gundersen Lutheran Medical Center
Address:
City:
La Crosse
Zip:
54601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
608-775-2385
Email:
cancerctr@gundersenhealth.org
Investigator:
Last name:
Collin D. Driscoll
Email:
Principal Investigator
Facility:
Name:
University of Wisconsin Carbone Cancer Center - University Hospital
Address:
City:
Madison
Zip:
53792
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-622-8922
Email:
clinicaltrials@cancer.wisc.edu
Investigator:
Last name:
Kari B. Wisinski
Email:
Principal Investigator
Facility:
Name:
Aurora Bay Area Medical Group-Marinette
Address:
City:
Marinette
Zip:
54143
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Milwaukee
Address:
City:
Milwaukee
Zip:
53209
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Saint Luke's Medical Center
Address:
City:
Milwaukee
Zip:
53215
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Sinai Medical Center
Address:
City:
Milwaukee
Zip:
53233
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Vince Lombardi Cancer Clinic - Oshkosh
Address:
City:
Oshkosh
Zip:
54904
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Racine
Address:
City:
Racine
Zip:
53406
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Vince Lombardi Cancer Clinic-Sheboygan
Address:
City:
Sheboygan
Zip:
53081
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Medical Center in Summit
Address:
City:
Summit
Zip:
53066
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Vince Lombardi Cancer Clinic-Two Rivers
Address:
City:
Two Rivers
Zip:
54241
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Milwaukee West
Address:
City:
Wauwatosa
Zip:
53226
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora West Allis Medical Center
Address:
City:
West Allis
Zip:
53227
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Puerto Rico Hematology Oncology Group
Address:
City:
Bayamon
Zip:
00961
Country:
Puerto Rico
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
787-780-2865
Investigator:
Last name:
Luis J. Santos Reyes
Email:
Principal Investigator
Facility:
Name:
Doctors Cancer Center
Address:
City:
Manati
Zip:
00674
Country:
Puerto Rico
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
787-621-4397
Investigator:
Last name:
Luis J. Santos Reyes
Email:
Principal Investigator
Facility:
Name:
Centro Comprensivo de Cancer de UPR
Address:
City:
San Juan
Zip:
00927
Country:
Puerto Rico
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-339-5294
Email:
Roster@nrgoncology.org
Investigator:
Last name:
Luis J. Santos Reyes
Email:
Principal Investigator
Facility:
Name:
PROncology
Address:
City:
San Juan
Zip:
00927
Country:
Puerto Rico
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
787-919-7919
Email:
info@PRoncology.com
Investigator:
Last name:
Luis J. Santos Reyes
Email:
Principal Investigator
Start date:
September 13, 2024
Completion date:
November 1, 2026
Lead sponsor:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Collaborator:
Agency:
NRG Oncology
Agency class:
Other
Source:
National Cancer Institute (NCI)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05554354
